301263.SHE Guangdong Taienkang Pharmaceutical Co. Ltd
- Market cap
- CNY 8.05B
- P/E
- 315.2x
- P/B
- 6.46x
- ROE
- 2.8%
- Dividend yield
- 1.16%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301263.SHE undervalued?
Graham numberThe Graham number of Guangdong Taienkang Pharmaceutical Co. Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangdong Taienkang Pharmaceutical Co. Ltd fundamental analysis
No fundamental analysis for Guangdong Taienkang Pharmaceutical Co. Ltd yet.
Guangdong Taienkang Pharmaceutical Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangdong Taienkang Pharmaceutical Co. Ltd
Guangdong Taienkang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers various products covering various therapeutic areas, including sexual health medicines, ophthalmic medicines, gastrointestinal medicines, Chinese patent medicines and external medicines, and sanitary materials in the form of tablets, pills, injections, and essential oils; medical technology and …
Full company profileGuangdong Taienkang Pharmaceutical Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangdong Taienkang Pharmaceutical Co. Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 496M | 709M | 654M | 783M | 761M | 721M | 675M | 710M |
| Gross Profit | 211M | 389M | 328M | 456M | 461M | 409M | 365M | 414M |
| Operating Income | 70.4M | 209M | 145M | 201M | 191M | 115M | 13.1M | 21.3M |
| EBITDA | 139M | 258M | 175M | 243M | 233M | 169M | 70.3M | 27.2M |
| Net Income | 54.9M | 161M | 120M | 175M | 160M | 108M | 28.6M | 42.0M |
| EPS | 0.35 | 0.50 | 0.38 | 0.34 | 0.31 | 0.25 | 0.06 | 0.08 |
| Balance Sheet | ||||||||
| Total Assets | 680M | 835M | 942M | 2.04B | 2.23B | 2.31B | 2.42B | 2.60B |
| Total Liabilities | 181M | 245M | 232M | 186M | 400M | 495M | 676M | 1.05B |
| Shareholders' Equity | 496M | 590M | 710M | 1.85B | 1.79B | 1.77B | 1.67B | 1.49B |
| Cash & Short-term Investments | 80.0M | 93.5M | 138M | 807M | 456M | 542M | 580M | 422M |
| Cash Flow | ||||||||
| Operating Cash Flow | 75.4M | 126M | 120M | 149M | 93.5M | 89.3M | -12.9M | - |
| Capital Expenditure | 8.83M | 93.1M | 44.6M | 89.9M | 200M | 68.6M | 108M | 159M |
| Free Cash Flow | 66.6M | 32.4M | 75.4M | 58.9M | -106M | 20.8M | -121M | -64.3M |
| Ratios | ||||||||
| ROE | 11.1% | 27.3% | 16.9% | 9.4% | 8.9% | 6.1% | 1.7% | 2.8% |
| ROA | 8.1% | 19.3% | 12.8% | 8.6% | 7.2% | 4.7% | 1.2% | 1.6% |
| Net Profit Margin | 11.1% | 22.7% | 18.4% | 22.3% | 21.1% | 15.0% | 4.2% | 5.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Guangdong Taienkang Pharmaceutical Co. Ltd dividends
- Dividend yield
- 1.16%
- Forward dividend
- 0.04 CNY
- Payout ratio
- 326.8%
- Ex-dividend date
- Jun 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 93.6M | 0.18 | 326.8% |
| 2024 | CNY 135M | 0.32 | 124.9% |
| 2023 | CNY 167M | 0.33 | 104.1% |
| 2022 | CNY 85.8M | 0.17 | 49.1% |
| 2021 | CNY 4.27M | 0.01 | 3.6% |
| 2020 | CNY 68.1M | 0.21 | 42.4% |
| 2019 | CNY 82.4M | 0.53 | 150.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 1, 2026.
Who owns Guangdong Taienkang Pharmaceutical Co. Ltd
- Insiders 49.02%
- Institutions 2.68%
- Public & others 48.30%
- Shares outstanding 425M
- Free float 342M
Guangdong Taienkang Pharmaceutical Co. Ltd company profile
- Company name
- Guangdong Taienkang Pharmaceutical Co. Ltd
- Ticker
- 301263.SHE
- ISIN
- CNE1000058X0
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,154
- Fiscal year end
- December
- Address
- Building A, Shantou, China, 515041
- Phone
- 86 754 8884 7515
- Website
- tai-kang.com.cn
About Guangdong Taienkang Pharmaceutical Co. Ltd
Guangdong Taienkang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers various products covering various therapeutic areas, including sexual health medicines, ophthalmic medicines, gastrointestinal medicines, Chinese patent medicines and external medicines, and sanitary materials in the form of tablets, pills, injections, and essential oils; medical technology and technology transfer services; and medical devices. It also operates as an agent for pharmaceutical products; and offers medical and sanitary materials, masks, sutures, surgical staplers, vascular clips and clip appliers, etc., as well as non-prescription drugs. The company was formerly known as Shantou Taikang Pharmaceutical Co., Ltd. and changed its name to Guangdong Taienkang Pharmaceutical Co., Ltd. in June 2006. Guangdong Taienkang Pharmaceutical Co., Ltd. was founded in 1999 and is headquartered in Shantou, China.
Guangdong Taienkang Pharmaceutical Co. Ltd management
6- Mr. Hanjie ZhengGM & Chairman · born 1963
- Ms. Guixi ZhouAccounting Supervisor & Financial Director · born 1987
- Mr. Ting LiDirector, Deputy GM & Secretary of the Board · born 1983
- Mr. Tao SunDeputy General Manager · born 1976
- Mr. Zhen ZhangDeputy General Manager · born 1976
- Ms. Zili LinDeputy General Manager · born 1976